FBXO3 and nonpapillary renal cell carcinoma: Patients with higher expressions of FBXL3 and FBXO3 presented a markedly prolonged survival in this study, illustrating that both of the two core FBGs could serve as biomarkers of immunotherapy for patients with ccRCC.